10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2022-02-14 (Q4 2021) | Holdings: 121 | Value: $20.6B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | Reduce 1% $(61.1M) | 35.27% | $7.2B | +12.64% | +12.25% | ||
| BGNE - BeiGene, Ltd. | 15.38% | $3.2B | +14.77% | -39.63% | +11.58% | ||
| INCY - Incyte Corporation | Add 5% ($117.1M) | 12.01% | $2.5B | -2.58% | +11.58% | +18.82% | |
| KOD - Kodiak Sciences Inc. | 6.06% | $1.2B | -93.79% | -89.59% | -86.53% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 4.76% | $978.2M | -18.08% | -36.95% | -27.95% | ||
| BMRN - BioMarin Pharmaceutical Inc. | 3.28% | $673.3M | -36.06% | -14.86% | +19.11% | ||
| ASND - Ascendis Pharma A/S | 2.97% | $611.0M | +32.05% | -31.29% | -9.18% | ||
| ARGX - argenx SE | 1.91% | $392.1M | +99.08% | +7.28% | +30.52% | ||
| MRTX - Mirati Therapeutics, Inc. | 1.01% | $206.8M | -45.13% | -52.67% | |||
| BCRX - BioCryst Pharmaceuticals, Inc. | 0.86% | $176.0M | -40.28% | -52.78% | -43.56% | ||
| KYMR - Kymera Therapeutics, Inc. | 0.74% | $151.4M | -27.83% | -59.61% | -19.65% | ||
| NVTA - Invitae Corporation | 0.73% | $150.8M | -65.17% | -79.65% | |||
| ABCL - AbCellera Biologics Inc. | 0.73% | $149.4M | -79.00% | -18.81% | +3.74% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.62% | $127.0M | +218.92% | -23.01% | +227.03% | ||
| PRLD - Prelude Therapeutics Inc. | 0.61% | $126.0M | -91.27% | -53.40% | -43.00% | ||
| LEGN - Legend Biotech Corporation | Add 5% ($5.8M) | 0.56% | $116.0M | -23.96% | +6.72% | +28.32% | |
| PACB - Pacific Biosciences of California, Inc. | 0.54% | $111.4M | -91.49% | -51.33% | -2.03% | ||
| GBT - Global Blood Therapeutics, Inc. | Add 3% ($2.8M) | 0.47% | $97.0M | -11.12% | |||
| CERS - Cerus Corporation | 0.45% | $93.4M | -76.26% | -5.61% | -43.55% | ||
| IGMS - IGM Biosciences, Inc. | 0.45% | $92.6M | -92.65% | -12.56% | +38.77% | ||
| IMCR - Immunocore Holdings plc | 0.42% | $86.3M | +60.81% | +30.93% | +183.52% | ||
| TVTX - Travere Therapeutics, Inc. | Add 31% ($19.5M) | 0.40% | $82.8M | -46.79% | -16.61% | -28.73% | |
| TRDA - Entrada Therapeutics, Inc. | New Purchase | 0.39% | $80.5M | -37.29% | -52.06% | -10.56% | |
| HRTX - Heron Therapeutics, Inc. | 0.36% | $74.2M | -78.34% | -59.22% | -69.70% | ||
| AMRN - Amarin Corporation plc | Reduce 3% $(2.3M) | 0.35% | $71.3M | -83.06% | -56.14% | -44.44% | |
| NRIX - Nurix Therapeutics, Inc. | 0.35% | $71.0M | -36.80% | -42.33% | -38.47% | ||
| TIL - Instil Bio, Inc. | 0.32% | $66.6M | -88.92% | -43.50% | -93.25% | ||
| MRUS - Merus N.V. | 0.32% | $64.8M | +117.16% | -38.11% | -27.92% | ||
| HZNP - Horizon Therapeutics Public Ltd Co | 0.31% | $64.6M | -7.47% | +11.75% | |||
| IMTX - Immatics N.V. | 0.29% | $59.5M | -39.98% | -29.18% | -11.25% | ||
| CCXI - ChemoCentryx, Inc. | New Purchase | 0.29% | $59.4M | -38.22% | |||
| INSM - Insmed Incorporated | 0.29% | $58.7M | +199.53% | -15.38% | -12.33% | ||
| NBIX - Neurocrine Biosciences, Inc. | 0.28% | $57.7M | +41.29% | -2.52% | +19.13% | ||
| KRYS - Krystal Biotech, Inc. | New Purchase | 0.27% | $56.5M | +93.58% | -12.80% | +12.97% | |
| VERV - Verve Therapeutics, Inc. | 0.25% | $52.2M | -85.30% | -54.44% | -28.25% | ||
| N/A - Apellis Pharmaceuticals, Inc. | Reduce 32% $(22.7M) | 0.23% | $48.0M | ||||
| VSTM - Verastem, Inc. | 0.21% | $44.1M | -53.23% | -23.13% | -55.77% | ||
| N/A - Insmed Incorporated | 0.21% | $43.3M | |||||
| N/A - Sarepta Therapeutics, Inc. | 0.21% | $42.7M | |||||
| RYTM - Rhythm Pharmaceuticals, Inc. | 0.19% | $38.6M | +865.83% | -49.29% | +315.12% | ||
| KDNY - Chinook Therapeutics, Inc. | New Purchase | 0.19% | $38.1M | +6.59% | +72.25% | ||
| RARE - Ultragenyx Pharmaceutical Inc. | 0.18% | $37.4M | -53.20% | -24.01% | -39.21% | ||
| ADAP - Adaptimmune Therapeutics plc | 0.18% | $36.9M | -90.71% | -54.92% | -47.62% | ||
| ALKS - Alkermes plc | Add 22% ($6.3M) | 0.17% | $34.9M | +35.08% | +25.62% | +17.19% | |
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.16% | $33.0M | +155.94% | -21.89% | +26.10% | ||
| DSGN - Design Therapeutics, Inc. | New Purchase | 0.15% | $30.8M | -74.97% | -20.07% | -53.89% | |
| TLIS - Talis Biomedical Corporation | Add 1% ($200.5K) | 0.15% | $30.6M | -95.12% | -50.73% | -70.18% | |
| FMTX - Forma Therapeutics Holdings, Inc. | 0.14% | $28.8M | -41.04% | ||||
| ZYME - Zymeworks Inc. | 0.14% | $28.0M | +55.51% | -27.35% | +20.68% | ||
| BLUE - bluebird bio, Inc. | 0.12% | $25.0M | -96.22% | -48.48% | -9.73% | ||
| AVTE - Aerovate Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | -72.11% | +23.01% | +179.64% | |
| ALGS - Aligos Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| ALLK - Allakos Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| DBVT - DBV Technologies S.A. | Reduce 100% | 0.00% | $0.00 | ||||
| FLGT - Fulgent Genetics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||